Advertorial

Merck recognised with INTERPHEX Exhibitor Award for Best New Product

0
SHARES

Posted: 10 April 2019 | | No comments yet

Merck wins award for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing…

bioprocessing Pellicon Capsule

Merck has announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next-generation bioprocessing. Merck’s Pellicon® Capsule with Ultracel® Membrane has been recognised for Best New Product.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

“This recognition is for an innovation that enables biomanufacturers to realise the benefits of process intensification throughout the entire bioprocess,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck.  “We will continue to revolutionise drug manufacturing with solutions that set the standard for improvements in process efficiency, simplified plant operations and consistency in manufacturing.”

Merck’s Pellicon Capsule with Ultracel Membrane is the first-of-its-kind single-use tangential flow filtration (TFF) capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies. The capsule reduces the risk of product cross-contamination, as well as exposure to highly toxic compounds during both processing and disassembly. The self-contained design is ideal for the safe and easy removal of the entire single-use TFF flow path immediately after product recovery, optimising product changeover efficiency and saving time. The device requires no cleaning validation requirements, thereby reducing its footprint in the manufacturing environment, which ultimately leads to increased plant productivity and process flexibility with the added benefit of reduced contamination risks.

Merck works with drug manufacturers to help bring life-enhancing drug therapies to market, faster. Its innovative technologies improve productivity, lower risks, reduce costs and ensure drug safety.

Related organisations

Related people

Share via
Share via